Cargando…

Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer

Colorectal cancer is the third leading cause of cancer-associated mortality in the western world. The ability to predict a patient's response to chemotherapy may be of great value for clinicians and patients when planning cancer treatment. The aim of the current study was to develop a urine met...

Descripción completa

Detalles Bibliográficos
Autores principales: Dykstra, Mark A., Switzer, Noah, Eisner, Roman, Tso, Victor, Foshaug, Rae, Ismond, Kathleen, Fedorak, Richard, Wang, Haili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666654/
https://www.ncbi.nlm.nih.gov/pubmed/29142749
http://dx.doi.org/10.3892/mco.2017.1407
_version_ 1783275346423971840
author Dykstra, Mark A.
Switzer, Noah
Eisner, Roman
Tso, Victor
Foshaug, Rae
Ismond, Kathleen
Fedorak, Richard
Wang, Haili
author_facet Dykstra, Mark A.
Switzer, Noah
Eisner, Roman
Tso, Victor
Foshaug, Rae
Ismond, Kathleen
Fedorak, Richard
Wang, Haili
author_sort Dykstra, Mark A.
collection PubMed
description Colorectal cancer is the third leading cause of cancer-associated mortality in the western world. The ability to predict a patient's response to chemotherapy may be of great value for clinicians and patients when planning cancer treatment. The aim of the current study was to develop a urine metabolomics-based biomarker panel to predict adverse events and response to chemotherapy in patients with colorectal cancer. A retrospective chart review of patients diagnosed with stage III or IV colorectal cancer between 2008 and 2012 was performed. The exclusion criteria included chemotherapy for palliation and patients living outside of Alberta. Data was collected concerning the chemotherapy regimen, adverse events associated with chemotherapy, disease progression and recurrence and 5-year survival. Adverse events were subdivided as follows: Delays in treatment, dose reductions, hospitalizations and chemotherapy regime changes. Patients provided urine samples for analysis prior to any intervention. Nuclear magnetic resonance (NMR) spectra of urine samples were acquired. The 1H NMR spectrum of each urine sample was analyzed using Chenomx NMRSuite v7.0. Using machine learning, predictors were generated and evaluated using 10-fold cross-validation. Urine spectra were obtained for 62 patients. The best predictors resulted in area under the receiver operating characteristic curve values of: 0.542 for chemotherapy dose reduction, 0.612 for 5-year survival, 0.650 for cancer recurrence and 0.750 for treatment delay. Therefore, predictors were developed for response to and adverse events from chemotherapy for patients with colorectal cancer patients. The predictor for treatment delay has the most promise, and further studies will aid its refinement and improvement of its accuracy.
format Online
Article
Text
id pubmed-5666654
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56666542017-11-15 Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer Dykstra, Mark A. Switzer, Noah Eisner, Roman Tso, Victor Foshaug, Rae Ismond, Kathleen Fedorak, Richard Wang, Haili Mol Clin Oncol Articles Colorectal cancer is the third leading cause of cancer-associated mortality in the western world. The ability to predict a patient's response to chemotherapy may be of great value for clinicians and patients when planning cancer treatment. The aim of the current study was to develop a urine metabolomics-based biomarker panel to predict adverse events and response to chemotherapy in patients with colorectal cancer. A retrospective chart review of patients diagnosed with stage III or IV colorectal cancer between 2008 and 2012 was performed. The exclusion criteria included chemotherapy for palliation and patients living outside of Alberta. Data was collected concerning the chemotherapy regimen, adverse events associated with chemotherapy, disease progression and recurrence and 5-year survival. Adverse events were subdivided as follows: Delays in treatment, dose reductions, hospitalizations and chemotherapy regime changes. Patients provided urine samples for analysis prior to any intervention. Nuclear magnetic resonance (NMR) spectra of urine samples were acquired. The 1H NMR spectrum of each urine sample was analyzed using Chenomx NMRSuite v7.0. Using machine learning, predictors were generated and evaluated using 10-fold cross-validation. Urine spectra were obtained for 62 patients. The best predictors resulted in area under the receiver operating characteristic curve values of: 0.542 for chemotherapy dose reduction, 0.612 for 5-year survival, 0.650 for cancer recurrence and 0.750 for treatment delay. Therefore, predictors were developed for response to and adverse events from chemotherapy for patients with colorectal cancer patients. The predictor for treatment delay has the most promise, and further studies will aid its refinement and improvement of its accuracy. D.A. Spandidos 2017-11 2017-09-01 /pmc/articles/PMC5666654/ /pubmed/29142749 http://dx.doi.org/10.3892/mco.2017.1407 Text en Copyright: © Dykstra et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Dykstra, Mark A.
Switzer, Noah
Eisner, Roman
Tso, Victor
Foshaug, Rae
Ismond, Kathleen
Fedorak, Richard
Wang, Haili
Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title_full Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title_fullStr Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title_full_unstemmed Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title_short Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
title_sort urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666654/
https://www.ncbi.nlm.nih.gov/pubmed/29142749
http://dx.doi.org/10.3892/mco.2017.1407
work_keys_str_mv AT dykstramarka urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT switzernoah urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT eisnerroman urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT tsovictor urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT foshaugrae urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT ismondkathleen urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT fedorakrichard urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer
AT wanghaili urinemetabolomicsasapredictorofpatienttoleranceandresponsetoadjuvantchemotherapyincolorectalcancer